regulator of G protein signaling 10Genealiases: []
Q-omics provides the consensus-scored RGS10 profile across patient tissues and cancer cell-line models. RGS10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RGS10 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, RGS10 protein abundance shows 22,102 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RGS10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS10 survival associations across molecular data types. RGS10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS10 RNA expression–survival associations across cancer types. High RGS10 expression shows unfavorable associations in KIRC, UVM and LAML, but favorable associations in UCEC, LUSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RGS10 RNA expression.
This table summarizes RGS10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RGS10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS10 shows higher tumor expression in KIRC, HNSC, LUAD, LIHC, KIRP and BRCA. The KIRC box plot shows higher RGS10 RNA expression in tumor versus normal tissue (log2 FC = +1.947, t-test p < 0.001).
This table shows molecular features associated with RGS10 in patient tissues and cancer cell lines. In patient samples, RGS10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
